Novo Nordisk bets big on obesity: Can marketing help it succeed in the notoriously tough therapy area?

Beth Snyder Bulik

Senior Editor

Queen Latifah is done. With weight jokes, judgy people, self-hate and a complicit media. Novo Nordisk’s newest face — and body — for anti-obesity awareness lays out …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novo Nordisk bets big on obesity: Can marketing help it succeed in the notoriously tough therapy area?

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

No­vo Nordisk bets big on obe­si­ty: Can mar­ket­ing help it suc­ceed in the no­to­ri­ous­ly tough ther­a­py area?

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

more like this

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Novo Nordisk bets big on obesity: Can marketing help it succeed in the notoriously tough therapy area?

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam